12:00 AM
Nov 22, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

IR501 Therapeutic Vaccine: Phase IIb

Data from 24 weeks in IMNR’s 340-patient Phase IIb trial showed a statistically significant improvement in ACR20 response following the third intramuscular injection of 30 ug IR501 compared to placebo...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >